Application of polymorphisms of vascular endothelial growth factor in evaluating the prognosis of hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment
10.3969/j.issn.1008-794X.2015.05.008
- VernacularTitle:血管内皮生长因子基因型对介入化疗栓塞治疗原发性肝癌预后的评估
- Author:
Lizhou WANG
;
Xing LI
;
Jie SONG
;
Tianpeng JIANG
;
Xiaoping WU
;
Shi ZHOU
- Publication Type:Journal Article
- Keywords:
clinical outcome;
polymorphism;
hepatocellular carcinoma;
vascular endothelial growth factor
- From:
Journal of Interventional Radiology
2015;(5):396-399
- CountryChina
- Language:Chinese
-
Abstract:
Objective Through detecting the genotypes of vascular endothelial growth factor (VEGF) to investigate the correlation between the different VEGF genotypes and survival rate of patients with hepatocellular carcinoma (HCC) after receiving transcatheter arterial chemoembolization (TACE). Methods A total of 156 patients with pathologically confirmed HCC, who were admitted to authors’ hospital during the period from January 2008 to January 2009 and received TACE within 2 months after the disease was confirmed by pathology, were included in this study. The genotypes of VEGF-2578C/A, -1154G/A, -634C/G, and-1498T/C were determined using a blood kit on a 384-well plat. The clinical data were collected, and the correlations between the genotypes and the patient’s prognosis were analyzed. Results In this study, a total of four genotypes were detected, including VEGF-2578C/A, VEGF-1154G/A, VEGF-634C/G and VEGF-1498T/C. The mean 5-year survival rate was 55.47%. Multivariate analysis revealed that only the tumor-node-metastasis(TNM) stage, metastasis, and the VEGF-2578 AA and VEGF-1154 AA genotypes were independent prognostic factors. HCC of TNM stage Ⅲ-Ⅳ would greatly increase the risk of death in HCC patients (HR=3.64, 95%CI=1.67-6.79; HR=2.91, 95%CI=1.30-6.27). Moreover, the death risk in patients with the VEGF-2578 AA and VEGF-1154 AA genotypes was much higher than that in patients with the wild-type genotype (HR=3.65, 95%CI=1.35-11.13; HR=7.13, 95%CI=1.46-65.8). Conclusion VEGF-2578C/A genotype and VEGF-1154G/A genotype are closely related to the prognosis of HCC patients after TACE treatment, which may be helpful for predicting the clinical outcome of HCC patients after interventional treatment.
